共 50 条
LncRNA H19: A Novel Biomarker in Cardiovascular Disease
被引:1
|作者:
Li, Xiaojun
[1
]
Zhang, Yugui
[2
]
Ding, Zhaoran
[3
]
Chen, Yijun
[4
]
Wang, Wei
[5
]
机构:
[1] Guangzhou Univ Chinese Med, Basic Med Coll, Guangzhou, Peoples R China
[2] Guangzhou Univ Chinese Med, Coll Pharm, Guangzhou, Peoples R China
[3] Gansu Univ Chinese Med, Coll Integrat Med, Lanzhou, Peoples R China
[4] Guangzhou Univ Chinese Med, Sch Basic Med, Guangzhou, Peoples R China
[5] Guangzhou Univ Tradit Chinese Med, Univ Town, Sch Basic Med, 232 Waihuan East Rd, Guangzhou, Guangdong, Peoples R China
基金:
中国国家自然科学基金;
关键词:
Cardiovascular disease;
LncRNA H19;
Novel biomarker;
LONG NONCODING RNA;
REGULATES CARDIOMYOCYTE APOPTOSIS;
ISCHEMIA-REPERFUSION INJURY;
EXPRESSION;
AXIS;
MECHANISM;
MARKER;
GROWTH;
CELLS;
D O I:
10.6515/ACS.202403_40(2).20230925A
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Cardiovascular disease is a major cause of death and disability worldwide. Recently, increasing evidence has demonstrated that long non -coding RNAs (lncRNAs) play critical roles in the pathogenesis of cardiovascular diseases, including atherosclerosis, coronary artery disease, dilated cardiomyopathy, diabetic cardiomyopathy, aortic dissection, and more. LncRNA H19 was the first to be described as a non -protein -coding mRNA-like molecule. A large number of studies have found that lncRNA H19 is related to the pathophysiological processes of cardiovascular diseases, and it is emerging as a potential key regulator of various heart diseases. In this review, we aim to summarize the role of lncRNA H19 in cardiovascular diseases in order to provide a theoretical basis for its potential use as a new therapeutic target in the future.
引用
收藏
页码:172 / 181
页数:10
相关论文